Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).

被引：0

作者：

Bosse, Dominick

Xie, Wanling

Wells, Connor

Lalani, Aly-Khan A.

Donskov, Frede

Bent, Alisha

Sim, Hao-Wen

Beuselinck, Benoit

Bamias, Aristotelis

Porta, Camillo

Vaishampayan, Ulka N.

Pal, Sumanta K.

Agarwal, Neeraj

Srinivas, Sandy

Rini, Brian I.

Alva, Ajjai Shivaram

Wood, Lori

Kapoor, Anil

Choueiri, Toni K.

Heng, Daniel Yick Chin

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[3] Tom Baker Canc Clin, Calgary, AB, Canada

[4] Aarhus Univ Hosp, Aarhus, Denmark

[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA

[6] Peter MacCallum Canc Ctr, Melbourne, Australia

[7] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, KU Leuven, Leuven, Belgium

[8] Univ Athens, Dept Clin Therapeut, Athens, Greece

[9] IRCCS San Matteo Univ Hosp Fdn, Padua, Italy

[10] Karmanos Canc Inst, Detroit, MI USA

[11] City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA

[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[13] Stanford Univ, Stanford, CA USA

[14] Cleveland Clin, Taussig Canc Insitute, Cleveland, OH USA

[15] Univ Michigan, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI USA

[16] QEII Hlth Sci Ctr, Halifax, NS, Canada

[17] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada

[18] Brigham & Womens Hosp, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.e16065

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16065

引用

页数：5

共 50 条

[1] The impact of MET expression on patient outcomes with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT)
Albiges, Laurence
De Velasco, Guillermo
Gray, Kathryn P.
Carol, Hallie A.
Caella, Marcella
Mickey, Suzanne S.
Fay, Andre P.
Mcdermott, David F.
Atkins, Michael B.
Heng, Daniel Y.
Signoretti, Sabina
Choueiri, Toni K.
BJU INTERNATIONAL, 2015, 116 : 1 - 2
[2] Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy
Golshayan, A. R.
George, S.
Heng, D. Y.
Elson, P.
Wood, L.
Garcia, J. A.
Aydin, H.
Zhou, M.
Bukowski, R. M.
Rini, B. I.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[3] Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome
Sadeghi, S.
Albiges, L.
Wood, L. S.
Black, S. L.
Gilligan, T. D.
Dreicer, R.
Garcia, J. A.
Escudier, B. J.
Rini, B. I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[4] The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
Fay, Andre Poisl
de Velasco, Guillermo
Gray, Kathryn P.
Ho, Thai Huu
Song, Jiaxi
Kapur, Payal
Albiges, Laurence
McDermott, David F.
Heng, Daniel Yick Chin
Brugarolas, James
Choueiri, Toni K.
Signoretti, Sabina
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[5] Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy
Golshayan, A.
Choueiri, T. K.
Elson, P.
Garcia, J. A.
Khaswneh, M.
Usman, S.
Tamaskar, I.
Wood, L.
Rini, B. I.
Bukowski, R. M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[6] Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy
Wood, L.
Bukowski, R. M.
Dreicer, R.
Elson, P.
Garcia, J. A.
Gilligan, T.
Mekhail, T.
Rini, B. I.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7] Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next?
Vickers, M. M.
Choueiri, T. K.
Zama, I.
Cheng, T.
North, S.
Knox, J. J.
Kollmannsberger, C.
McDermott, D. F.
Rini, B. I.
Heng, D. Y.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[8] The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts)
Al-Marrawi, M. Y.
Rini, B. I.
Harshman, L. C.
Bjarnason, G. A.
Wood, L.
Vaishampayan, U. N.
MacKenzie, M. J.
Knox, J. J.
Agarwal, N.
Kollmannsberger, C. K.
Tan, M.
Rha, S. Y.
Donskov, F.
North, S. A.
Choueiri, T. K.
Heng, D. Y. C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[9] Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).
de Velasco, Guillermo
Xie, Wanling
Donskov, Frede
Albiges, Laurence
Beuselinck, Benoit
Srinivas, Sandhya
Agarwal, Neeraj
Lee, Jae-Lyun
Brugarolas, James
Wood, Lori
Kollmannsberger, Christian K.
Rha, Sun Young
North, Scott A.
Kanesvaran, Ravindran
Rini, Brian I.
Broom, Reuben James
Yamamoto, Haru
Kaymakcalan, Marina Dusevic
Heng, Daniel Yick Chin
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[10] The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
Ernst, Matthew Scott
Abou Alaiwi, Sarah
Dizman, Nazli
Labaki, Chris
Nuzzo, Pier Vitale
Adib, Elio
Schmidt, Andrew Lachlan
Meza, Luis A.
Gan, Chun Loo
Wells, J. Connor
Bakouny, Ziad
Pal, Sumanta K.
Choueiri, Toni K.
Heng, Daniel Yick Chin
Dudani, Shaan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →